ArticleBMC infectious diseases2025
Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research progress on the association between viruses and cardiac diseases.Journal of virology · 2026Review
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHuman Cytomegalovirus (HCMV) spreads through direct contact with blood, and other body fluids such as urine, saliva and breast milk. It is transmitted sexually and can also be passed from a pregnant mother to fetus via the placenta. While often asymptomatic in healthy individuals, HCMV causes symptomatic infections in immunocompromised people and congenital infections in fetuses. It is a common global congenital infection and can lead to morbidity and occasional mortality in newborns. Latent HCMV may reactivate in immunosuppressed individuals. This study aimed to determine the age and gender specific seroprevalence of HCMV in selected populations in Sri Lanka.
methodsA total of 820 blood samples obtained from 820 participants of selected low and high-risk populations in Sri Lanka, namely; hospital inpatients (n = 200), antenatal women (n = 80), blood donors (n = 80), cancer patients (n = 200), Sexually Transmitted Disease (STD) clinic attendees (n = 160) and Chronic Kidney Disease (CKD) patients on haemodialysis (n = 100) were tested for IgG antibodies against HCMV by Enzyme Linked Immunosorbent Assay (ELISA). Statistical analysis was performed using IBM SPSS Statistics version 30 (IBM
resultsOverall HCMV seroprevalence was found to be 94.9% (778/820), whereas in males it was 95.2% (395/415) and in females it was 94.6% (383/405) (p = 0.691). Seroprevalence of HCMV in hospital inpatients, antenatal women, blood donors, cancer patients, STD clinic attendees and CKD patients on haemodialysis were found to be 92.5% (185/200), 100% (80/80), 90% (72/80), 96% (192/200), 93.1% (149/160) and 100% (100/100) respectively. Overall seroprevalence of HCMV increases with age ranging from 94.3% (33/35) in 15-19 years age group to 98.8% (84/85) in ≥ 60 years age group.
conclusionsSeroprevalence of HCMV in diverse low and high-risk populations of Sri Lanka was studied for the first time. HCMV seroprevalence is similar between genders (p > 0.05) and increases with age. Over 90% of individuals are infected with HCMV by age 15, indicating a high prevalence of primary infections from early childhood to adolescence. This study provides essential background information on HCMV infection and its impacts in diverse populations of Sri Lanka and aids in executing preventive and therapeutic measures in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.